Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2008

Metabolon and the Harvard-Partners Healthcare Collaborate to Refine Warfarin Theranostic

  • Metabolon and the Harvard-Partners Healthcare Center for Genetics and Genomics (HPCGG) are working together to improve diagnostic tests related to warfarin dosing. The collaborators say that they will not only examine a patient’s genetics but also the metabolomic profile to determine the correct dosing regimen for this blood-thinning agent.

    Patient samples for the study are being collected as part of the ongoing HPCGG trial called Creating an Optimal Warfarin Nomogram (CROWN). It is a prospective dosing study that is focusing on genetic testing to determine the optimal warfarin dose. Sample collection for the diagnostic development should be complete in the summer. Metabolon will then conduct the metabolomic analysis.

    HPCGG investigators also have received preferred access to Metabolon's global biochemical profiling platform. These services provide for the extraction, identification, and quantitation of small molecules. The platform also highlights significantly altered metabolites related to these biochemicals.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »